Monomethyl fumarate

Research use only, not for human use.

Monomethyl fumarate is a potent agonist of GPR109A .

Monomethyl fumarate is a potent agonist of GPR109A .(In Vitro):Monomethyl fumarate (25 μM; 24?hours) attenuates 7β-OHC-induced cytotoxicity: cell growth inhibition; decreased cell viability; mitochondrial dysfunction; and cell death induction.

Monomethyl fumarate completely inhibits forskolin induced cAMP synthesis with an IC50 of 70 nM. Monomethyl fumarate induces a dose-dependent Ca2+ signal in GPR109A transfected cells with an EC50 of 9.4 μM. Monomethyl fumarate (25 μM; 24?hours) attenuates 7β-OHC-induced cytotoxicity: cell growth inhibition; decreased cell viability; mitochondrial dysfunction; and cell death induction.

A single dose of Monomethyl fumarate (50-100 mg/kg; IP) before light exposure prevents these morphologic changes (bright light exposure induced photoreceptor death) in a dose-dependent manner. Monomethyl fumarate (100 mg/kg) reduces retinal inflammation and oxidative stress. Monomethyl fumarate significantly suppresses light-induced retinopathy (LIR) upregulated genes in the NFkB pathway including: Nlrp3, Casp1, Il-1β, and Tnf-α. Animal Model:Albino BALB/c mice (male, 6 weeks old)Dosage:50, 65, 75, 100 mg/kg Administration:IP Result:Prevented these morphologic changes (bright light exposure induced photoreceptor death) in a dose-dependent manner.

——

Cell Cycle/DNA Damage

GPR

——

——

——

2756-87-8

130.099

C5H6O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (384.32 mM)

COC(=O)\C=C\C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years